| Source | Code | Name | Case count | Share of cases (%) |
|---|---|---|---|---|
| PURCH | PURCH_ATC(L01XE33) | [U] palbociclib | 354 | |
| PURCH | PURCH_ATC(L01XE04) | [U] sunitinib | 292 | |
| PURCH | PURCH_ATC(L01XE01) | [U] imatinib | 289 | |
| PURCH | PURCH_ATC(L01XE31) | [U] nintedanib | 194 | |
| PURCH | PURCH_ATC(L01XE11) | [U] pazopanib | 148 | |
| PURCH | PURCH_ATC(L01XE05) | [U] sorafenib | 129 | |
| PURCH | PURCH_ATC(L01XE26) | [U] cabozantinib | 116 | |
| PURCH | PURCH_ATC(L01XE03) | [U] erlotinib | 111 | |
| PURCH | PURCH_ATC(L01XE23) | [U] dabrafenib | 109 | |
| PURCH | PURCH_ATC(L01XE10) | [U] everolimus | 104 | |
| PURCH | PURCH_ATC(L01XE27) | [U] ibrutinib | 90 | |
| PURCH | PURCH_ATC(L01XE13) | [U] afatinib | 81 | |
| PURCH | PURCH_ATC(L01XE25) | [U] trametinib | 79 | |
| PURCH | PURCH_ATC(L01XE21) | [U] regorafenib | 75 | |
| PURCH | PURCH_ATC(L01XE18) | [U] ruxolitinib | 69 | |
| PURCH | PURCH_ATC(L01XE17) | [U] axitinib | 59 | |
| PURCH | PURCH_ATC(L01XE07) | [U] lapatinib | 53 | |
| PURCH | PURCH_ATC(L01XE06) | [U] dasatinib | 48 | |
| PURCH | PURCH_ATC(L01XE02) | [U] gefitinib | 47 | |
| PURCH | PURCH_ATC(L01XE08) | [U] nilotinib | 39 | |
| PURCH | PURCH_ATC(L01XE16) | [U] crizotinib | 24 | |
| PURCH | PURCH_ATC(L01XE35) | [U] osimertinib | 23 | |
| PURCH | PURCH_ATC(L01XE36) | [U] alectinib | 23 | |
| PURCH | PURCH_ATC(L01XE29) | [U] lenvatinib | 20 | |
| PURCH | PURCH_ATC(L01XE15) | [U] vemurafenib | 19 | |
| PURCH | PURCH_ATC(L01XE41) | [U] binimetinib | 15 | |
| PURCH | PURCH_ATC(L01XE46) | [U] encorafenib | 15 | |
| PURCH | PURCH_ATC(L01XE14) | [U] bosutinib | 11 | |
| PURCH | PURCH_ATC(L01XE24) | [U] ponatinib | 6 |